Snehal Patel Buys 6,000 Shares of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Stock
Greenwich LifeSciences, Inc. (NASDAQ:GLSI – Get Rating) CEO Snehal Patel bought 6,000 shares of the firm’s stock in a transaction dated Tuesday, June 7th. The shares were acquired at an average price of $8.55 per share, for a total transaction of $51,300.00. Following the completion of the transaction, the chief executive officer now directly owns 1,238,953 shares in the company, valued at approximately $10,593,048.15. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Snehal Patel also recently made the following trade(s):
- On Thursday, June 2nd, Snehal Patel purchased 6,774 shares of Greenwich LifeSciences stock. The stock was bought at an average price of $7.38 per share, with a total value of $49,992.12.
- On Thursday, April 21st, Snehal Patel acquired 6,000 shares of Greenwich LifeSciences stock. The stock was bought at an average cost of $16.09 per share, with a total value of $96,540.00.
- On Tuesday, April 19th, Snehal Patel bought 6,000 shares of Greenwich LifeSciences stock. The stock was bought at an average price of $16.74 per share, with a total value of $100,440.00.
GLSI stock opened at $8.52 on Wednesday. Greenwich LifeSciences, Inc. has a 12 month low of $6.90 and a 12 month high of $48.96. The company has a 50-day moving average price of $12.87 and a 200 day moving average price of $19.59.
Hedge funds and other institutional investors have recently made changes to their positions in the business. OLD Mission Capital LLC bought a new stake in shares of Greenwich LifeSciences during the third quarter worth $287,000. D. E. Shaw & Co. Inc. purchased a new position in Greenwich LifeSciences in the 4th quarter worth about $254,000. UBS Group AG lifted its holdings in Greenwich LifeSciences by 467.1% during the 3rd quarter. UBS Group AG now owns 4,310 shares of the company’s stock valued at $168,000 after buying an additional 3,550 shares in the last quarter. Morgan Stanley boosted its position in Greenwich LifeSciences by 21.5% in the 1st quarter. Morgan Stanley now owns 4,622 shares of the company’s stock valued at $158,000 after buying an additional 819 shares during the period. Finally, Royal Bank of Canada grew its stake in Greenwich LifeSciences by 22.6% in the 3rd quarter. Royal Bank of Canada now owns 3,771 shares of the company’s stock worth $147,000 after acquiring an additional 695 shares in the last quarter. 6.15% of the stock is owned by institutional investors and hedge funds.
Separately, Zacks Investment Research upgraded Greenwich LifeSciences from a “sell” rating to a “hold” rating in a research report on Monday, May 30th.
About Greenwich LifeSciences (Get Rating)
Greenwich LifeSciences, Inc, a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.
Receive News & Ratings for Greenwich LifeSciences Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Greenwich LifeSciences and related companies with MarketBeat.com’s FREE daily email newsletter.